skip to content

Department of Oncology



Duncan Jodrell is the Professor of Cancer Therapeutics at the University of Cambridge, the Director of the Cambridge Cancer Trials Centre and the co-Lead for Experimental Cancer Medicine at the CRUK Cambridge Centre.   Duncan moved to Cambridge from Edinburgh in 2008, establishing and leading an Early Phase clinical trials’ team.  He has a special interest in novel therapeutic approaches for the treatment of patients with pancreatic cancer.   A Medical Oncologist (an honorary consultant at Cambridge University Hospitals NHS Trust), Duncan completed his doctoral thesis at the Institute of Cancer Research and an MSc in Biochemistry at King’s College (University of London), post-doctoral research at the University of Maryland (Baltimore) and completed his clinical training at the Royal Marsden Hospital (London) and Beatson Oncology Centre (Glasgow).  Duncan has acted as the Chief or Principal Investigator in many Early Phase and Experimental Medicine studies, in addition to leading innovative laboratory research.

Key areas of interest:


I endeavour to integrate and optimise the pre-clinical development and science-led clinical application of novel therapies and novel therapeutic combinations, including first into man (phase I) and associated studies.  My research goal is to identify successful, new therapeutic approaches for the treatment of patients with cancer with much of my effort focussing on pancreatic cancer.


Cambridge ECMC Early Phase Trials team portfolio:


The ATRiUM clinical trial:


Key publications: 

Defining the spatial distribution of extracellular adenosine revealed a myeloid-dependent immunosuppressive microenvironment in pancreatic ductal adenocarcinoma.

Graziano V, Dannhorn A, Hulme H, Williamson K, Buckley H, Karim SA, Wilson M, Lee SY, Kaistha BP, Islam S, Thaventhiran JED, Richards FM, Goodwin R, Brais R, Morton JP, Dovedi SJ, Schuller AG, Eyles J, Jodrell DI. J Immunother Cancer. 2023 Aug;11(8):e006457. doi: 10.1136/jitc-2022-006457.


Size-tuneable and immunocompatible polymer nanocarriers for drug delivery in pancreatic cancer.

Popov AB, Melle F, Linnane E, González-López C, Ahmed I, Parshad B, Franck CO, Rahmoune H, Richards FM, Muñoz-Espín D, Jodrell DI, Fairen-Jimenez D, Fruk L. Nanoscale. 2022 May 5;14(17):6656-6669. doi: 10.1039/d2nr00864e.


CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response.

Biasci D, Smoragiewicz M, Connell CM, Wang Z, Gao Y, Thaventhiran JED, Basu B, Magiera L, Johnson TI, Bax L, Gopinathan A, Isherwood C, Gallagher FA, Pawula M, Hudecova I, Gale D, Rosenfeld N, Barmpounakis P, Popa EC, Brais R, Godfrey E, Mir F, Richards FM, Fearon DT, Janowitz T, Jodrell DI. Proc Natl Acad Sci U S A. 2020 Nov 17;117(46):28960-28970. doi: 10.1073/pnas.2013644117. Epub 2020 Oct 30.


The ATR Inhibitor AZD6738 Synergizes with Gemcitabine In Vitro and In Vivo to Induce Pancreatic Ductal Adenocarcinoma Regression.

Wallez Y, Dunlop CR, Johnson TI, Koh SB, Fornari C, Yates JWT, Bernaldo de Quirós Fernández S, Lau A, Richards FM, Jodrell DI. Mol Cancer Ther. 2018 Aug;17(8):1670-1682. doi: 10.1158/1535-7163.MCT-18-0010. Epub 2018 Jun

Teaching and Supervisions

Research supervision: 

Clinical Trial Fellows

Other Professional Activities

  • Director, Cambridge Cancer Trials Centre
  • Co-Lead Cambridge Experimental Cancer Medicine Centre
  • Honorary Consultant in Medical Oncology (Cambridge University Hospitals NHS Trust)
  • Fellow of the Association of Cancer Physicians UK
  • Fellow of the Royal College of Physicians of Edinburgh
Professor of Cancer Therapeutics
Professor Duncan  Jodrell

Contact Details

Cancer Research UK Cambridge Institute
University of Cambridge
Li Ka Shing Centre
Box 278 Cambridge Biomedical Campus
Robinson Way
Available for consultancy